Docetaxel (Taxotere) plus 6-Month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial.

Trial Profile

Docetaxel (Taxotere) plus 6-Month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Docetaxel (Primary) ; Antiandrogens
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 03 Aug 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jan 2019, as reported by ClinicalTrials.gov.
    • 03 Aug 2015 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top